Thermosomes may also be a good candidate to enhance delivery of your compound

© iStock poba
© iStock poba

Thermosome’s proprietary platform technology can be used for delivery of various active pharmaceutical ingredients (APIs) with its application sweet spot being localized diseases. While our own drug development focuses on locally-advanced solid tumors, our TSL technology can be applied in multiple indications and therapeutic areas far beyond oncology.

In various proof-of-concept formulation studies, we have encapsulated in our nanocarrier system various compounds, both hydrophilic and hydrophobic APIs, and thereby proven the broad applicability of our platform technology. Besides benefits of better local delivery, some clinical applications may additionally benefit from synergies of the application of mild (hyperthermic) heat at 40-42°C, which our system uses as an external trigger. While not yet fully understood by academia, the application of mild heat is supposed to cause several effects, such as blocking cell survival, inducing cellular stress responses, modulating immune responses, evading DNA repair, changing the tumor microenvironment and/or sensitizing cells to chemotherapy and radiotherapy. As an example, drugs in the field of immuno-oncology, which need a localized targeted delivery, may additionally benefit from these synergistic effects.

Partnering opportunities

If you have a compound that may benefit from targeted delivery, we are happy to discuss its feasibility for local drug delivery through our Thermosomes. We are also interested in discussions for development partnerships and alliances of our own drug candidates. For further information, please contact us at or give us a call. Beside, you can also meet us at the following up-coming BD events:

BioEurope Spring 2018
November 5-7, 2018
Kopenhagen, Denmark

J.P. Morgan 37th Annual Healthcare Conference 2019
January 7-10, 2019
San Francisco, USA

Bio 2019
June 3-6, 2019
Philadelphia, USA